Navigation Links
Oncobiologics, Inc. Announces a Collaboration Agreement with XOMA Corporation to Utilize XOMA's Fully Human Antibody Libraries for Their Discovery Platform

CRANBURY, N.J., July 30, 2012 /PRNewswire/ -- Oncobiologics, Inc. announced today a collaboration agreement with XOMA Corporation to develop novel biotherapeutics based on engineering single-chain variable fragments (scFv) into a bi-specific antibody scaffold. Through the partnership, Oncobiologics will utilize XOMA's ADAPT™ fully human antibody technology platform as a key component of its drug discovery program. Oncobiologics has selected clinically validated targets that will be used in the development of its bi-specific antibody platform targeting three therapeutic areas: Oncology, Immuno-Oncology and Immunology.

Under the agreement, Oncobiologics will gain access to XOMA's highly diverse library of scFv antibodies and associated patent estate, and will utilize XOMA's know-how and proven software tools as it advances its own candidates for treating cancer and immune diseases. Financial terms were not disclosed.

Pankaj Mohan, Ph.D., Founder & CEO of Oncobiologics, commented, "We are very excited to partner with XOMA to advance our discovery pipeline. Their proven technology represents an important asset to support our strategy to deliver improved efficacy and safety in our drug candidates. Access to this technology is a key differentiator for the bi-specific mAb candidates in our pipeline and we believe this creates significant value for our programs."

Joseph Bertino, M.D., Chief Scientific Officer of the Cancer Institute of New Jersey and Head of Oncobiologics' Scientific Advisory Board, added, "Fully human single chain antibodies in a bi-specific format offer promising opportunities for a new class of biotherapeutics designed to enhance efficacy and safety. Bringing together these capabilities with Oncobiologics' platform creates an exciting pathway for enhancing oncology treatment."

About Oncobiologics, Inc.

Headquartered in Cranbury, N.J., Oncobiologics is a biopharmaceutical company developing a pipeline of next generation biotherapeutics focused on clinically validated targets in the therapeutic areas of oncology, immuno-oncology, and immunology. The company's proprietary TriDENT™ platform leverages fully human single-chain, bi-specific antibodies with HSA binding designed for overall significantly enhanced efficacy, safety, and pharmacokinetics with targeted delivery.  For more information, please visit or call 609-619-3990.


Stephen J. McAndrew, Ph.D.
Oncobiologics, Inc.
609-619-3990, ext. 216

Rick Gregory

This press release was issued through eReleases® Press Release Distribution. For more information, visit  

SOURCE Oncobiologics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. MiMedx Group Announces Record Second Quarter Results
2. Verenium Announces EPA Authorization To Market Its Next-Generation Enzyme Breaker For Hydraulic Fracturing
3. PhoenixSongs Biologicals, Inc. Announces Enhanced Neural Lineage-specific Cell Culture Media Products Release
4. Leading India-USA based CRO Announces Data Management/EDC, Medical Writing Milestone
5. IDEXX Laboratories Announces Second Quarter Results
6. Amgen Announces 2012 Third Quarter Dividend
7. Merck Company Foundation Announces HIV Care Collaborative with Atlanta, Houston and Philadelphia Health Departments
8. Critical Process Filtration Announces New Website and Expanded Literature Library
9. Sangamo BioSciences Announces Second Quarter 2012 Conference Call and Webcast
10. Neogen Corporation Announces Year-End Results Conference Call
11. Convergence Pharmaceuticals Announces Successful Completion of Phase I for CNV2197944 and Plans Phase II Studies in Neuropathic Pain
Post Your Comments:
(Date:11/25/2015)... , November 25, 2015 2 ... première fois les différences entre les souches bactériennes ... celles des êtres humains . Ces recherches ... et envisager la prise en charge efficace de ... diagnostiqués chez les chats .    --> ...
(Date:11/25/2015)... QUEBEC CITY , Nov. 25, 2015 /PRNewswire/ ... "Company"), affirms that its business and prospects remain ... , Zoptrex™ (zoptarelin doxorubicin) recently received DSMB ... program to completion following review of the final ... met Phase 2 Primary Endpoint in men with ...
(Date:11/25/2015)... San Francisco, CA (PRWEB) , ... November 25, ... ... leading microbial genomics company uBiome, were featured on AngelList early in their initial ... by launching an AngelList syndicate for individuals looking to make early stage investments ...
(Date:11/24/2015)... Nov. 24, 2015 Halozyme Therapeutics, Inc. (NASDAQ: HALO ... New York on Wednesday, December 2 at ... , president and CEO, will provide a corporate overview. ... at 1:00 p.m. ET/10:00 a.m. PT . ... will provide a corporate overview. --> th Annual ...
Breaking Biology Technology:
(Date:11/10/2015)... 10, 2015  In this report, the ... of product, type, application, disease indication, and ... report are consumables, services, software. The type ... biomarkers, efficacy biomarkers, and validation biomarkers. The ... diagnostics development, drug discovery and development, personalized ...
(Date:11/9/2015)... 9, 2015  Synaptics Inc. (NASDAQ: SYNA ), ... broader entry into the automotive market with a comprehensive ... pace of consumer electronics human interface innovation. Synaptics, industry-leading ... for the automotive industry and will be implemented in ... Europe , Japan , and ...
(Date:10/29/2015)...   MedNet Solutions , an innovative SaaS-based eClinical ... research, is pleased to announce that it has been ... one of only three finalists for a 2015 ... Growing" category. The Tekne Awards honor Minnesota ... innovation and leadership. iMedNet™ eClinical ...
Breaking Biology News(10 mins):